Phát triển các đối kháng thụ thể CRF1 như thuốc chống trầm cảm và an thần

Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int J Methods Psychiatr Res 2003; 12(1): 3–21 Kessler RC, Dernier O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005 Jun 16; 352(24): 2515–23 DuPont RL, Rice DP, Miller LS, et al. Economic costs of anxiety disorders. Anxiety 1996; 2(4): 167–72 Lenze EJ, Mulsant BH, Shear MK, et al. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry 2000 May; 157(5): 722–8 Vale W, Spiess J, Rivier C, et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213: 1394–7 Vale W, Rivier C, Brown MR, et al. Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res 1983; 39: 245–70 Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 1990; 15: 71–100 Koob GF, Heinrichs SC, Menzaghi F, et al. Corticotropin releasing factor, stress, and behavior. Seminars Neurosci 1994; 6: 221–9 Koob GF, Heinrichs SC. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 1999; 848(1–2): 141–52 Smith MA, Davidson J, Ritchie JC, et al. The corticotropin-releasing hormone test in patients with posttraumatic stress disorder. Biol Psychiatry 1989 Aug; 26(4): 349–55 Nemeroff CB, Widerlov E, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984 Dec 14; 226(4680): 1342–4 Galard R, Catalan R, Castellanos JM, et al. Plasma corticotropin-releasing factor in depressed patients before and after the dexamethasone suppression test. Biol Psychiatry 2002 Mar 15; 51(6): 463–8 Nemeroff CB, Owens MJ, Bissette G, et al. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988 Jun; 45(6): 577–9 Raadsheer FC, Hoogendijk WJ, Stam FC, et al. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994 Oct; 60(4): 436–44 Roy-Byrne PP, Uhde TW, Post RM, et al. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 1986 Jul; 143(7): 896–9 Sutton RE, Koob GF, Le Moal M, et al. Corticotropin releasing factor produces behavioural activation in rats. Nature 1982; 297(5864): 331–3 Koob GF, Swerdlow N, Seeligson M, et al. Effects of alpha-flupenthixol and naloxone on CRF-induced locomotor activation. Neuroendocrinology 1984; 39(5): 459–64 Britton KT, Morgan J, Rivier J, et al. Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology 1985; 86(1–2): 170–4 Swerdlow NR, Geyer MA, Vale WW, et al. Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology 1986; 88(2): 147–52 Cole BJ, Koob GF. Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor. J Pharmacol Exp Ther 1988; 247(3): 902–10 Krahn DD, Gosnell BA, Grace M, et al. CRF antagonist partially reverses CRF- and stress-induced effects on feeding. Brain Res Bull 1986; 17(3): 285–9 Arase K, York DA, Shimizu H, et al. Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. Am J Physiol 1988; 255 (3 Pt 1): E255–9 Stenzel-Poore MP, Heinrichs SC, Rivest S, et al. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 1994; 14 (5 Pt 1): 2579–84 Swerdlow NR, Britton KT, Koob GF. Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharmacology 1989; 2(4): 285–92 Menzaghi F, Howard RL, Heinrichs SC, et al. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther 1994; 269(2): 564–72 Macey DJ, Koob GF, Markou A. CRF and urocortin decreased brain stimulation reward in the rat: reversal by a CRF receptor antagonist. Brain Res 2000; 866(1–2): 82–91 Spina MG, Basso AM, Zorrilla EP, et al. Behavioral effects of central administration of the novel CRF antagonist astressin in rats. Neuropsychopharmacology 2000; 22(3): 230–9 Heinrichs SC, Menzaghi F, Pich EM, et al. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology 1994; 11(3): 179–86 Behan DP, Grigoriadis DE, Lovenberg T, et al. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiatry 1996; 1(4): 265–77 Valdez GR, Inoue K, Koob GF, et al. Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 2002; 943(1): 142–50 Smith GW, Aubry JM, Delhi F, et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20(6): 1093–102 Timpl P, Spanagel R, Sillaber I, et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998; 19(2): 162–6 Contarino A, Dellu F, Koob GF, et al. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res 1999; 835(1): 1–9 Contarino A, Dellu F, Koob GF, et al. Dissociation of locomotor activation and suppression of food intake induced by CRF in CRFR1-deficient mice. Endocrinology 2000; 141(7): 2698–702 Heinrichs SC, Lapsansky J, Lovenberg TW, et al. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept 1997; 71(1): 15–21 Liebsch G, Landgraf R, Engelmann M, et al. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res 1999; 33(2): 153–63 Skutella T, Probst JC, Renner U, et al. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience 1998; 85(3): 795–805 Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 1995; 15(10): 6340–50 Perrin M, Donaldson C, Chen R, et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A 1995; 92(7): 2969–73 Spina M, Merlo-Pich E, Chan RK, et al. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996; 273(5281): 1561–4 Pelleymounter MA, Joppa M, Carmouche M, et al. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J Pharmacol Exp Ther 2000; 293(3): 799–806 Bale TL, Contarino A, Smith GW, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000; 24(4): 410–4 Kishimoto T, Radulovic J, Radulovic M, et al. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 2000; 24(4): 415–9 Isogawa K, Akiyoshi J, Tsutsumi T, et al. Anxiogenic-like effect of corticotropin-releasing factor receptor 2 antisense oligonucleotides infused into rat brain. J Psychopharmacol 2003 Dec; 17(4): 409–13 Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 2001; 98(5): 2843–8 Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 2001; 98(13): 7570–5 Valdez GR, Zorrilla EP, Rivier J, et al. Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 2003; 980: 206–12 Venihaki M, Sakihara S, Subramanian S, et al. Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol 2004 May; 16(5): 411–22 Takahashi LK, Ho SP, Livanov V, et al. Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 2001; 902(2): 135–42 Pelleymounter MA, Joppa M, Ling N, et al. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 2002 Jul; 302(1): 145–52 Ho SP, Takahashi LK, Livanov V, et al. Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Brain Res 2001; 89(1–2): 29–40 Radulovic J, Ruhmann A, Liepold T, et al. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 1999; 19(12): 5016–25 Menard J, Treit D. Lateral and medial septal lesions reduce anxiety in the plus-maze and probe-burying tests. Physiol Behav 1996; 60(3): 845–53 Yadin E, Thomas E, Grishkat HL, et al. The role of the lateral septum in anxiolysis. Physiol Behav 1993; 53(6): 1077–83 Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287–92 de Groote L, Penalva RG, Flachskamm C, et al. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists. J Neurochem 2005 Jul; 94(1): 45–56 Schulz DW, Mansbach RS, Sprouse J, et al. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 1996 Sep 17; 93(19): 10477–82 Mansbach RS, Brooks EN, Chen YL. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 1997 Mar 26; 323(1): 21–6 Maier SF, Seligman MEP. Learned helplessness: theory and evidence. J Exp Psychol Gen 1976; 105: 3–46 Takamori K, Kawashima N, Chaki S, et al. Involvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats. Life Sci 2001 Aug 3; 69(11): 1241–8 Takamori K, Kawashima N, Chaki S, et al. Involvement of the hypothalamus-pituitary-adrenal axis in antidepressant activity of corticotropin-releasing factor subtype 1 receptor antagonists in the rat learned helplessness test. Pharmacol Biochem Behav 2001 Jul–Aug; 69(3–4): 445–9 Chaki S, Nakazato A, Kennis L, et al. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA 0450. Eur J Pharmacol 2004 Feb 6; 485(1–3): 145–58 Li YW, Fitzgerald L, Wong H, et al. The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists. CNS Drug Rev 2005 Spring; 11(1): 21–52 Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatment. Nature 1977; 266: 730–2 Webster EL, Lewis DB, Torpy DJ, et al. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996 Dec; 137(12): 5747–50 Jutkiewicz EM, Wood SK, Houshyar H, et al. The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berl) 2005 Jul; 180(2): 215–23 Nielsen DM, Carey GJ, Gold LH. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol. 2004 Sep 19; 499(1–2): 135–46 Griebel G, Simiand J, Steinberg R, et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II: characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 2002 Apr; 301(1): 333–45 Yamano M, Yuki H, Yasuda S, et al. Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther 2000 Jan; 292(1): 181–7 Overstreet DH, Friedman E, Mathe AA, et al. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev 2005; 29(4–5): 739–59 Overstreet DH, Griebel G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 2004 Aug 16; 497(1): 49–53 Overstreet DH, Keeney A, Hogg S. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. Eur J Pharmacol 2004 May 25; 492(2–3): 195–201 Ducottet C, Griebel G, Beizung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 2003 Jun; 27(4): 625–31 Alonso R, Griebel G, Pavone G, et al. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 2004 Mar; 9(3): 278–86 Griebel G, Perrault G, Sanger DJ. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents: comparison with diazepam and buspirone. Psychopharmacology (Berl) 1998; 138(1): 55–66 Robison CL, Meyerhoff JL, Saviolakis GA, et al. A CRH1 antagonist into the amygdala of mice prevents defeat-induced defensive behavior. Ann N Y Acad Sci 2004 Dec; 1032: 324–7 Keck ME, Welt T, Wigger A, et al. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 2001 Jan; 13(2): 373–80 Zorrilla EP, Valdez GR, Nozulak J, et al. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 2002 Oct 18; 952(2): 188–99 Lelas S, Wong H, Li YW, et al. Anxiolytic-like effects of the corticotropin-releasing factor 1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5 -a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. J Pharmacol Exp Ther 2004 Apr; 309(1): 293–302 Deak T, Nguyen KT, Ehrlich AL, et al. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 1999; 140(1): 79–86 Gehlert DR, Shekhar A, Morin SM, et al. Stress and central urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur J Pharmacol 2005 Feb 21; 509(2–3): 145–53 Harro J, Tonissaar M, Eller M. The effects of CRA 1000, a nonpeptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat. Neuropeptides 2001 Apr; 35(2): 100–9 Zobel AW, Nickel T, Kunzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000 May–Jun; 34(3): 171–81 Kunzel HE, Zobel AW, Nickel T, et al. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 2003 Nov–Dec; 37(6): 525–33 Held K, Kunzel H, Ising M, et al. Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res 2004 Mar–Apr; 38(2): 129–36 Kunzel HE, Ising M, Zobel AW, et al. Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression. J Psychiatr Res 2005 Mar; 39(2): 173–7 Zorrilla EP, Koob GF. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 2004 Jul; 13(7): 799–828 Bornstein SR, Webster EL, Torpy DJ, et al. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Enocrinology 1998 Apr; 139(4): 1546–55 Broadbear JH, Winger G, Rice KC, et al. Antalarmin, a putative CRH-RI antagonist, has transient reinforcing effects in rhesus monkeys. Psychopharmacology (Berl) 2002 Nov; 164(3): 268–76